When was AvenCell founded?

AvenCell was founded in 2021 and raised its 1st funding round within a year of its incorporation.

Where is AvenCell located?

AvenCell is headquartered in Watertown, United States. It is registered at Tatzberg 47, 01307 Dresden.

Which legal entities is AvenCell associated with?

AvenCell is associated with Avencell Europe Gmbh and 1 other.

How many employees does AvenCell have?

As of Mar 31, 2026, the latest employee count at AvenCell is 66.

Is AvenCell a funded company?

AvenCell is a funded company, having raised a total of $362M across 4 funding rounds to date. The company's 1st funding round was a $***** Series A round, raised on Jun 22, 2021.

When was the latest funding round of AvenCell?

AvenCell's latest funding was a $***** Grant (prize money) round on Jul 02, 2025, with participation from 1 investor. Its primary sector is Immunotherapy. In United States, the Immunotherapy sector has seen $843M in funding in 2026 to date.

Where does AvenCell rank among its competitors?

AvenCell ranks 302nd amongst 3426 active competitors, of which 1188 are funded. It stands 3rd in terms of total funding among its competitors. The most recent competitor to raise funding was AvenCell, which secured $40M in Jul, 2025.

Who are the top competitors of AvenCell?

AvenCell's top competitors include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Among them, AvenCell secured the most recent funding round in July, 2025.

AvenCell - 2026 Company Profile, Team, Funding & Competitors

AvenCell is a series B company based in Watertown (United States), founded in 2021. It operates as a Developer of next-generation switchable CAR T-cell immunotherapies. AvenCell has raised $362M in funding from Novo Holdings. The company has 3426 active competitors, including 1188 funded and 818 that have exited. Its top competitors include companies like Jazz Pharmaceuticals, argenx and Sana Biotechnology.

Company Details

Developer of next-generation switchable CAR T-cell immunotherapies. This company develops allogeneic platforms to address shortcomings of current T cell-based immunotherapies. Their technology offers powerful controllability of CAR-T reactivity while maintaining high anti-tumor activity. A switchable on/off mechanism, using universal effector cells and soluble adaptors, allows precise targeting of cancer antigens. Rapid switchability lowers the risk of side effects, improving the therapeutic window and safety. The focus is on overcoming limitations of current CAR-T cell therapies.

Website: avencell.com
Email ID: *****@avencell.com
Phone Number: +1 **********
Registered Address: Tatzberg 47, 01307 Dresden

Key Metrics

Founded Year

2021

Location

Watertown, United States

Stage

Series B

Total Funding

$362M in 4 rounds

Latest Funding Round

Grant (prize money), Jul 02, 2025, $*****

Investors

Novo Holdings & 9 more

Ranked

302^nd among 3426 active competitors

Employee Count

66 as on Mar 31, 2026

Similar Companies

Jazz Pharmaceuticals & 3317 more

View AvenCell's full profile

AvenCell is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
AVENCELL THERAPEUTICS, INC CIN: 87-1778098 , United States, Active	Jan 10, 2023	-	26 (As on Dec 31, 2023)	-
Avencell Europe Gmbh CIN: U1104_HRB30429 , Germany, Active	Sep 22, 2011	-	79 (As on Dec 31, 2023)

AvenCell has raised a total funding of $362M over 4 rounds. Its first funding round was on Jun 22, 2021. Its latest funding round was a Grant (prize money) round on Jul 02, 2025 for $*****. 1 investor participated in its latest round. AvenCell has 10 institutional investors.

Here is the list of recent funding rounds of AvenCell:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Jul 02, 2025	6974847	Grant (prize money)	3224949	1361479	7613049	1032708
Oct 22, 2024	1386692	Series B	5845056	1012044	5899083	Blackstone & 4 more
Feb 01, 2023	6452146	Grant (prize money)	6518638	7690486	1478455	Europa

Access funding benchmarks and valuations. Sign up today!

View details of AvenCell's funding rounds and investors

AvenCell's employee count trend

AvenCell has 66 employees as of Mar 26. Here is AvenCell's employee count trend over the years:

Uncover AvenCell's growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of AvenCell include Jazz Pharmaceuticals, argenx and Sana Biotechnology. Here is the list of Top 10 competitors of AvenCell, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, KKR & 14 others	82/100
2nd	argenx 2008, Ghent (Belgium), Public	Developer of antibody-based drugs to treat autoimmune diseases and cancer	$61.9M	Life Sciences Partners, Omnes Capital & 20 others	76/100
3rd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of genetically engineered cell therapies for multiple disorders	$821M	Baillie Gifford, Google Ventures & 17 others	75/100
4th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	75/100
5th	Blueprint Medicines 2008, Cambridge (United States), Acquired	Developer of selective kinase inhibitors for patients with genomically defined cancers	$115M	Third Rock Ventures, Nextech Invest & 20 others	73/100
6th	Kronos Bio 2017, San Mateo (United States), Acquired	Developer of small molecule based therapeutics for cancer treatment	$271M	Omega Funds, Vida Ventures & 18 others	72/100
7th	BeiGene 2010, Cambridge (United States), Public	Developer of targeted and immune-oncology drugs against cancer	$172M	Hillhouse, Boxer Capital & 13 others	72/100
8th	MacroGenics 2000, Rockville (United States), Public	Developer of novel biologics for the treatment of autoimmune disorders, cancer and infectious disease	$126M	Nextech Venture, Ventures West & 29 others	72/100
9th	Regeneron Pharmaceuticals 1988, Tarrytown (United States), Public	Developer of antibodies for the treatment of cancer, eye diseases, inflammatory diseases & others	-	BB Biotech, Kaccelerator & 7 others	71/100
10th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, Astrazeneca & 31 others	71/100
302nd	AvenCell 2021, Watertown (United States), Series B	Developer of next-generation switchable CAR T-cell immunotherapies	$362M	F-Prime Capital, Eight Roads Ventures & 8 others	58/100